.png){kind=icon}
.png){kind=icon}
Return
From Failure to Success: Evaluating Infliximab Efficacy After Adalimumab Failure in Hidradenitis Suppurativa
.png){kind=icon}
OA
AI
R
J
E
R
B
N
Z
DOI：10.1155/dth/9020978.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Hidradenitis suppurativa (HS) is a debilitating, chronic skin disease. Although adalimumab is a Food and Drug Administration (FDA)–approved biologic drug to treat HS, a significant number of patients develop primary or secondary failure to this treatment. Limited data exist in the literature on the effectiveness of the infliximab medication in such a group of patients. This study assesses the effectiveness and safety of infliximab treatment in patients diagnosed with HS whose adalimumab therapy has failed.
Keywords:
adalimumab failure
Dermatology Life Quality Index
hidradenitis suppurativa
hidradenitis suppurativa clinical response
infliximab therapy
Journal
IF:
3.4
Papers:
4.8K
Citations:
7.1K
Organization
Cited Papers